Distinguished for setting new benchmarks last year, Celtic Biotech Ltd won Biotech Company of the Year at the Pharma Industry Awards 2025, celebrated for its groundbreaking work in developing natural peptides for cancer treatment and advancing innovative therapeutic solutions in the biotech sector.

Founded by Dr. Paul and John Reid, Celtic Biotech’s lead candidate, CB-24, a novel receptor-binding protein currently in Phase I trials, demonstrates the company’s commitment to delivering first-in-class treatments with the potential to significantly improve patient outcomes. 

Despite its small size, the team has shown remarkable capability in combining cutting-edge research with entrepreneurial execution, positioning Celtic Biotech as a rising force in Ireland’s life sciences landscape.

Judges praised the company’s vision and impact: “Celtic Biotech impressed our panel with its extraordinary achievements and clear strategic focus. The team’s ability to innovate, adapt, and thrive in a highly challenging sector highlights the very best of Ireland’s emerging scientific and startup excellence,” the judging panel said.

Celtic Biotech’s recognition reflects the increasing standards across the Pharma Industry Awards, where winners are celebrated for pioneering innovation, operational precision, and measurable impact on patient care and scientific advancement. The company’s success illustrates how ambition, expertise, and perseverance can drive both therapeutic progress and industry leadership.

With exceptional leadership from the 2025 winners, attention now turns to the next awards cycle. Who will define the next era of innovation, scientific excellence, and patient-focused biotech leadership in 2026?

For years, the Pharma Industry Awards bring together senior executives, researchers, and innovators from across the life sciences sector to celebrate transformative achievements and leadership.

Visit the official awards website to explore past winners, read more about their achievements, and subscribe to the newsletter for updates and insights.